Physician profile

Alice Diku

Child & Adolescent Psychiatry · Orangeburg, NY

NPI 1629291620

$2,428.54

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$935.55

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Axsome Therapeutics, INC. $611.14 2023-2024 Auvelity
Otsuka Pharmaceutical Development & Commercialization, INC. $474.64 2019-2024
Janssen Pharmaceuticals, INC $415.70 2019
Otsuka America Pharmaceutical, INC. $358.39 2019-2022
Sunovion Pharmaceuticals INC. $239.07 2019-2020
Allergan, INC. $124.98 2020
Bioxcel Therapeutics, INC. $120.10 2023 Igalmi
Jazz Pharmaceuticals INC. $84.52 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Alice Diku

$2,428.54

in general payments reported 2019-2025

Years
2019-2024
Top company
Axsome Therapeutics, INC.

https://glasscript.com/doctor/119290/alice-diku

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.